Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus

Annals of Pharmacotherapy

Volumn 44, Issue 7-8, 2010, Pages 1294-1300

  Tzefos, Maria ^a,b   Olin, Jacqueline L ^a,c  

^a WINGATE UNIVERSITY   (United States)

^b Cabarrus Family Medicine   (United States)

^c Matthews Free Medical Clinic   (United States)

Author keywords

Exenatide; Insulin; Liraglutide; Type 2 diabetes mellitus

Indexed keywords

CREATININE; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; LIRAGLUTIDE; ANTIDIABETIC AGENT; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PEPTIDE; VENOM;

CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC PATIENT; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; KIDNEY DYSFUNCTION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREATITIS; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION; AGONISTS; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOPHYSIOLOGY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PEPTIDES; RECEPTORS, GLUCAGON; VENOMS;

EID: 77954579761     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P047     Document Type: Review

References (25)

1. American Diabetes Association. National diabetes fact sheet, 2007. www.diabetes.org/diabetes-basics/diabetes-statistics/ (accessed 2010 Jan 23).
2. Standards of medical care in diabetes - 2010. Diabetes Care 2010;33 (suppl 1):S11-61.
3. Centers for Disease Control and Prevention, National Center for Health Statistics. www.cdc.gov/diabetes/statistics/meduse/fig1.htm (accessed 2010 Jan 23).
4. Product information. Byetta (exenatide). San Diego, CA: Amylin Pharmaceuticals, Inc., October 2009.
5. Robles G, Singh-Franco D. A review of exenatide as adjunctive therapy in patients with type 2 diabetes. Drug Des Devel Ther 2009;3:219-40.
6. Govindan JP, Healey B, Kalupahana DN, et al. Exenatide therapy in insulin treated patients with type 2 diabetes and obesity (abstract 884). Diabetologia 2008;51(suppl 1):S352-3.
7. Samarasinghe YP, Shlomowitz A, Munro N, et al. The short term effects of exenatide therapy in insulin treated patients with type 2 diabetes mellitus - a new option to achieve weight loss (abstract 885). Diabetologia 2008;51(suppl 1):S353.
8. Christofidis EA, Boyle PJ, Johnson MT. Real world clinical experience with exenatide, a long term study on weight and A1C control (abstract 572-P). Diabetes 2009;58(suppl 1):A154.
9. Bhatia R, Viswanathan P, Chaudhuri A, et al. Exenatide causes weight loss and a reduction in the insulin dose along with an improvement in HbA1C in obese type 2 diabetics on insulin (abstract 442-P). Diabetes 2006;55(suppl 1):A105.
10. Oyer DS, Crawford RS, Shah A, et al. Exenatide in diabetic patients on insulin and TZDs (abstract 2038-PO). Diabetes 2006;55(suppl 1):A471-2.
11. Viswanathan P, Chaudhuri A, Bhatia R, et al. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007;13:444-50.
12. Hood RC. Exenatide (EXE) use in T2DM with A1C≤7% (abstract 488-P). Diabetes 2006;55(suppl 1):A116.
13. Sheffield CA, Kane MP, Busch RS, et al. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008;14:285-92.
14. Yoon NM, Cavaghan MK, Brunelle RL, et al. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009;31:1511-23.
15. John LE, Kane MP, Busch RS, et al. Expanded use of exenatide in the management of type 2 diabetes. Diabetes Spectrum 2007;20:59-63.
16. Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007;64:317-27.
17. Johansen OE, Whitfield R. Exenatide may aggravate moderate diabetic renal impairment: a case report. Br J Clin Pharmacol 2008;66:568-9.
18. Adjunctive therapy of exenatide or sitagliptin to insulin glargine in type 2 diabetes (identifier: NCT00971659). www.clinicaltrials.gov (accessed 2010 Jan 23).
19. Comparison of two basal insulins for patients with type 2 diabetes taking oral diabetes medicines and exenatide. (Identifier: NCT00560417). www. clinicaltrials.gov (accessed 2010 Jan 23).
20. Addition of exenatide to insulin glargine in type 2 diabetes mellitus. (Identifier: NCT00765817). www.clinicaltrials.gov (accessed 2010 Jan 23).
21. A new treatment strategy of adding exenatide to insulin therapy for patients with type 2 diabetes (T2DM) and non-alcoholic fatty liver disease (NAFLD). (Identifier: NCT01006889). www.clinicaltrials.gov (accessed 2010 Jan 23).
22. How glargine insulin, oral diabetes medications and exenatide may improve blood sugar control and weight gain in type 2 diabetics (MEXELIN). (Identifier: NCT00667732). www.clinicaltrials.gov (accessed 2010 Jan 23).
23. A trial comparing two therapies: basal insulin/glargine, exenatide and metformin (BET) or basal insulin/glargine, bolus insulin lispro and metformin (BBT) in subjects with type 2 diabetes. (Identifier: NCT00960661). www.clinicaltrials.gov (accessed 2010 Jan 23).
24. The effect of insulin detemir in combination with liraglutide and metformin compared with liraglutide and metformin in subjects with type 2 diabetes. (Identifier: NCT00856986). www.clinicaltrials.gov (accessed 2010 Mar 11).
25. Examination of the effects of liraglutide on the mode of action of insulin detemir. (Identifier: NCT00873223). www.clinicaltrials.gov (accessed 2010 Mar 11).